Verve Therapeutics (VERV) Competitors $5.74 +0.58 (+11.24%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends VERV vs. GLPG, XNCR, EVO, ARQT, NRIX, RCUS, KNSA, IMCR, OCUL, and MESOShould you be buying Verve Therapeutics stock or one of its competitors? The main competitors of Verve Therapeutics include Galapagos (GLPG), Xencor (XNCR), Evotec (EVO), Arcutis Biotherapeutics (ARQT), Nurix Therapeutics (NRIX), Arcus Biosciences (RCUS), Kiniksa Pharmaceuticals (KNSA), Immunocore (IMCR), Ocular Therapeutix (OCUL), and Mesoblast (MESO). These companies are all part of the "pharmaceutical products" industry. Verve Therapeutics vs. Galapagos Xencor Evotec Arcutis Biotherapeutics Nurix Therapeutics Arcus Biosciences Kiniksa Pharmaceuticals Immunocore Ocular Therapeutix Mesoblast Verve Therapeutics (NASDAQ:VERV) and Galapagos (NASDAQ:GLPG) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, dividends, risk, community ranking, profitability, analyst recommendations, media sentiment, earnings and institutional ownership. Do insiders and institutionals hold more shares of VERV or GLPG? 97.1% of Verve Therapeutics shares are held by institutional investors. Comparatively, 32.5% of Galapagos shares are held by institutional investors. 19.3% of Verve Therapeutics shares are held by insiders. Comparatively, 2.9% of Galapagos shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Does the MarketBeat Community favor VERV or GLPG? Galapagos received 442 more outperform votes than Verve Therapeutics when rated by MarketBeat users. Likewise, 64.10% of users gave Galapagos an outperform vote while only 53.33% of users gave Verve Therapeutics an outperform vote. CompanyUnderperformOutperformVerve TherapeuticsOutperform Votes2453.33% Underperform Votes2146.67% GalapagosOutperform Votes46664.10% Underperform Votes26135.90% Which has better earnings & valuation, VERV or GLPG? Galapagos has higher revenue and earnings than Verve Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVerve Therapeutics$24.40M19.92-$200.07M-$2.46-2.33Galapagos$260.09M6.78$229.12MN/AN/A Is VERV or GLPG more profitable? Galapagos has a net margin of 0.00% compared to Verve Therapeutics' net margin of -807.65%. Galapagos' return on equity of 0.00% beat Verve Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Verve Therapeutics-807.65% -35.23% -27.65% Galapagos N/A N/A N/A Does the media favor VERV or GLPG? In the previous week, Verve Therapeutics and Verve Therapeutics both had 2 articles in the media. Galapagos' average media sentiment score of 0.68 beat Verve Therapeutics' score of 0.52 indicating that Galapagos is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Verve Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Galapagos 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend VERV or GLPG? Verve Therapeutics presently has a consensus target price of $25.75, indicating a potential upside of 348.61%. Galapagos has a consensus target price of $30.75, indicating a potential upside of 14.91%. Given Verve Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Verve Therapeutics is more favorable than Galapagos.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Verve Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Galapagos 2 Sell rating(s) 5 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.71 Which has more volatility & risk, VERV or GLPG? Verve Therapeutics has a beta of 1.71, suggesting that its stock price is 71% more volatile than the S&P 500. Comparatively, Galapagos has a beta of 0.23, suggesting that its stock price is 77% less volatile than the S&P 500. SummaryGalapagos beats Verve Therapeutics on 8 of the 15 factors compared between the two stocks. Ad Crypto Swap ProfitsURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.>> Register for the Workshop Now Get Verve Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VERV and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VERV vs. The Competition Export to ExcelMetricVerve TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$485.97M$6.58B$5.13B$9.07BDividend YieldN/A2.99%5.08%4.23%P/E Ratio-2.3310.5489.7417.18Price / Sales19.92195.791,116.12116.95Price / CashN/A57.1642.8237.86Price / Book0.795.094.774.78Net Income-$200.07M$151.83M$120.15M$225.60M7 Day Performance0.53%-2.13%-1.92%-1.23%1 Month Performance24.78%-3.10%11.47%3.36%1 Year Performance-59.26%11.54%30.52%16.60% Verve Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VERVVerve Therapeutics1.9654 of 5 stars$5.74+11.2%$25.75+348.6%-57.7%$485.97M$24.40M-2.33110High Trading VolumeGLPGGalapagos0.6163 of 5 stars$27.00+0.7%$30.75+13.9%-31.4%$1.78B$260.09M0.001,123XNCRXencor4.3204 of 5 stars$25.02+4.1%$36.56+46.1%+18.4%$1.75B$168.34M-7.51280EVOEvotec2.387 of 5 stars$4.68+4.2%$5.93+26.8%-60.5%$1.66B$777.05M0.005,061Positive NewsARQTArcutis Biotherapeutics0.855 of 5 stars$13.31+4.9%$15.50+16.5%+478.8%$1.56B$138.71M-7.58150Options VolumeNRIXNurix Therapeutics2.5066 of 5 stars$21.13+4.2%$30.35+43.6%+101.7%$1.50B$56.42M-6.97300News CoverageRCUSArcus Biosciences2.6428 of 5 stars$16.25+1.1%$34.00+109.2%-9.3%$1.49B$117M-5.11500News CoverageKNSAKiniksa Pharmaceuticals2.5299 of 5 stars$20.50+1.5%$36.60+78.5%+15.4%$1.48B$384.10M-147.36220Positive NewsIMCRImmunocore2.4959 of 5 stars$29.12+0.7%$65.64+125.4%-51.4%$1.46B$296.31M-30.43497Short Interest ↓OCULOcular Therapeutix3.6452 of 5 stars$9.04+4.0%$16.71+84.9%+116.8%$1.42B$58.44M0.00267Positive NewsMESOMesoblast1.0377 of 5 stars$12.16+3.4%$11.50-5.4%+590.1%$1.39B$5.90M0.0080Analyst ForecastOptions VolumeNews CoverageGap Down Related Companies and Tools Related Companies Galapagos Competitors Xencor Competitors Evotec Competitors Arcutis Biotherapeutics Competitors Nurix Therapeutics Competitors Arcus Biosciences Competitors Kiniksa Pharmaceuticals Competitors Immunocore Competitors Ocular Therapeutix Competitors Mesoblast Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:VERV) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Verve Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Verve Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free VERV Stock Alerts